Lee Anderson
About Lee Anderson
Lee Anderson was appointed Chief Commercial Officer of Sera Prognostics on May 8, 2025, bringing 30+ years of commercial leadership in diagnostics across sales, marketing, strategic accounts, and customer service, with senior roles at Genomic Health, Exact Sciences, and Biofidelity; he holds a B.S. in Biology/Pre-Medicine with a Chemistry minor from Florida State University . During his early tenure, Sera reported Q3 2025 revenue of $16,000 vs. $29,000 in Q3 2024, total operating expenses of $9.0M vs. $8.9M, and net loss of $7.8M vs. $7.9M; cash and securities were ~$102.4M as of Sept 30, 2025 . Management disclosed the commercial expansion began in Q2 2025 with hiring an experienced CCO and building field sales in strategic geographies to drive PreTRM adoption .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Genomic Health (acquired by Exact Sciences) | Vice President, US Oncology Sales and Global Customer Service | — | Led US Oncology sales and global customer service; delivered nine consecutive years of revenue growth . |
| Exact Sciences | General Manager, Precision Oncology | — | Drove nationwide sales growth and launched innovative products . |
| Biofidelity Inc. | Chief Commercial Officer | — | Enhanced commercial strategy and advanced market presence . |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| — | — | — | No public company board roles disclosed in Sera’s press release or proxy materials referencing executive officers . |
Fixed Compensation
Compensation terms for Lee Anderson (base salary, target bonus, equity grant values) were not disclosed in the May 8, 2025 8-K (Reg FD press release furnished) and do not appear in the 2025 DEF 14A, which covers FY 2024 named executive officers as of March 31, 2025 and predates his appointment .
Performance Compensation
Plan metrics, weightings, targets, and payouts for Lee Anderson (e.g., revenue growth, PreTRM adoption, EBITDA/TSR) have not been disclosed in current SEC filings; the 8-K furnishing the appointment press release contains no compensatory detail . Sera’s bonus plan framework and 2024 metrics are described for other executives in the 2025 proxy, but not for Anderson .
Equity Ownership & Alignment
- Beneficial ownership: Anderson is not listed among beneficial owners or directors/officers in the ownership table as of March 31, 2025 (pre-appointment) .
- 10b5-1 plans: Q3 2025 10-Q reported adoptions for the CFO and a director; no plan adoption or termination disclosed for Anderson in the quarter .
- Hedging/pledging: Company insider trading policy prohibits short sales, margin pledging/loans, collars/hedges, and transactions in publicly traded options; pre-clearance required for executives and directors .
- Clawback: Board adopted an SEC/Nasdaq-compliant clawback policy on Oct 2, 2023, requiring recovery of excess incentive compensation upon an accounting restatement, regardless of fault .
Employment Terms
- Appointment: Lee Anderson appointed Chief Commercial Officer on May 8, 2025; announcement furnished under Item 7.01 without Item 5.02 compensation details .
- Offer letter/contract terms: No employment agreement, severance, or change-of-control terms for Anderson are disclosed in the appointment 8-K or the 2025 proxy .
- Company practices: Executive severance and equity acceleration constructs are detailed for other named executive officers in the 2025 proxy (e.g., single-trigger salary multiples and equity vesting partial acceleration; double-trigger full acceleration), but these do not cover Anderson .
Company Operating Context (for performance linkage)
| Metric | Q3 2024 | Q3 2025 |
|---|---|---|
| Revenue (USD) | $29,000 | $16,000 |
| Total Operating Expenses (USD) | $8.9M | $9.0M |
| R&D Expense (USD) | $3.5M | $3.3M |
| SG&A Expense (USD) | $5.4M | $5.7M |
| Net Loss (USD) | $7.9M | $7.8M |
| Cash, Cash Equivalents, and AFS Securities (USD) | — | ~$102.4M (as of 9/30/2025) |
Commercial ramp: Expansion began in Q2 2025 with hiring of an experienced CCO and field sales additions; focus on targeted geographies (Medicaid pilots, KOLs, PRIME sites) to build PreTRM adoption .
Investment Implications
- Alignment visibility gap: Absence of disclosed base salary, target bonus, equity grants, vesting schedules, and severance/CIC terms for Anderson limits pay-for-performance assessment and modeling of retention risk or potential insider selling pressure; monitor Form 4 filings and the next proxy for details .
- Governance mitigants: Prohibitions on hedging/pledging and a clawback policy improve alignment and reduce downside governance risk associated with incentive structures .
- Near-term catalysts: Management’s commercial build (Medicaid pilots, payer/provider engagement) is underway; Anderson’s impact should be observable in payer coverage traction and PreTRM test adoption KPIs over subsequent quarters .
- Watch items: Look for (i) any Rule 10b5-1 plan adoption by Anderson (pre-clearance required), (ii) disclosed equity grants/vesting cadence in upcoming filings, and (iii) concrete revenue and utilization milestones tied to compensation metrics to gauge pay-for-performance rigor .